• Fri, February 8, 2013

by: WOPRAI

VRNM SqueezeTrigger Price is $2.88. There is $1,266,720 That Short Sellers Still Need To Cover.

by: WOPRAI

FRAN SqueezeTrigger Price is $26.88. There is $354,456,234 That Short Sellers Still Need To Cover.

by: WOPRAI

HMST SqueezeTrigger Price is $28.01. There is $17,109,144 That Short Sellers Still Need To Cover.

by: WOPRAI

QLTY SqueezeTrigger Price is $8.38. There is $8,043,000 That Short Sellers Still Need To Cover.

by: WOPRAI

BBD SqueezeTrigger Price is $17.94. There is $370,349,785 That Short Sellers Still Need To Cover.

by: WOPRAI

Nanosphere Inc (NASDAQ:NSPH), Down By 6.46% ($0.19) From $2.940 After BUYINS.NET Report Predicted Stock Would Go Down Due To Be

by: WOPRAI

Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Down By 14.77% ($0.48) From $3.250 After BUYINS.NET Report Predicted Weakness After E

by: WOPRAI

Auxilium Pharmaceuticals Inc (NASDAQ:AUXL), Down By 6.28% ($1.17) From $18.640 After BUYINS.NET Report Predicted Weakness Befor

by: WOPRAI

Momenta Pharmaceuticals Inc (NASDAQ:MNTA), Down By 5.50% ($0.69) From $12.540 After BUYINS.NET Report Predicted Weakness Before

by: WOPRAI

PLOW SqueezeTrigger Price is $13.80. There is $12,087,600 That Short Sellers Still Need To Cover.

by: WOPRAI

ACFN SqueezeTrigger Price is $7.15. There is $25,677,930 That Short Sellers Still Need To Cover.

by: WOPRAI

OKS SqueezeTrigger Price is $58.46. There is $154,264,248 That Short Sellers Still Need To Cover.

by: WOPRAI

NTT SqueezeTrigger Price is $22.12. There is $22,923,720 That Short Sellers Still Need To Cover.

by: WOPRAI

CPSI SqueezeTrigger Price is $48.56. There is $28,164,351 That Short Sellers Still Need To Cover.

by: WOPRAI

PRIM, AAXJ, Removed From Naked Short Lists Today

by: WOPRAI

DARA, Added To Naked Short Lists Today

by: WOPRAI

ASTM Are Seasonally Ripe To Go Down In the Next Five Weeks

by: WOPRAI

CAMT, PFSW, RIGL, ALCO, RBY, ELNK Are Seasonally Ripe To Go Down In the Next Five Weeks

by: WOPRAI

SCR, LDK, FIG, NGSX, ESSA, DGICA Are Seasonally Ripe To Go Down In the Next Five Weeks

by: WOPRAI

ORN, FLIR, ATHX, GBNK, CUR, ENOC Are Seasonally Ripe To Go Down In the Next Five Weeks

by: WOPRAI

BNCL, PZN, LRN, EFSC, JACK, SILU Are Seasonally Ripe To Go Up In the Next Five Weeks

by: WOPRAI

GJR, DEF, OCLS, IBKR, BGS, SEP Are Seasonally Ripe To Go Up In the Next Five Weeks

by: WOPRAI

BWP, OPTR, WWWW, DBC, XBI, ISM Are Seasonally Ripe To Go Up In the Next Five Weeks

by: WOPRAI

MMLP, IAU, LABL, MOH, NGD, MWIV Are Seasonally Ripe To Go Up In the Next Five Weeks

by: WOPRAI

MCHX, TRLG, EPB, TBBK, IXC, BBL Are Seasonally Ripe To Go Up In the Next Five Weeks

by: WOPRAI

CUTR, LGF, CNO, TWTC, CGNX, VECO Expected To Be Up After Next Earnings Releases

by: WOPRAI

HERO Expected To Be Up Before Next Earnings Releases

by: WOPRAI

VRS, ASTE, B, BWA, AFSI, JNY Expected To Be Up Before Next Earnings Releases

by: WOPRAI

OTTR, CPST, MAS, ACGL, UNIS Expected To Be Down After Next Earnings Releases

by: WOPRAI

OMI, AFG, PKY, LDR, CRK, API Expected To Be Down After Next Earnings Releases

by: WOPRAI

PTN Expected To Be Down Before Next Earnings Releases

by: WOPRAI

CNSL, CSIQ, NX, NXTM, GOV, MTG Expected To Be Down Before Next Earnings Releases

by: WOPRAI

David Wright Upgraded (VOD) to Strong Buy on, Feb 8th, 2013

by: WOPRAI

Philip Ng Maintained (VMC) at Strong Buy with Increased Target to $63 on, Feb 8th, 2013

by: WOPRAI

Kenneth Zaslow Maintained (ANDE) at Hold with Increased Target to $35 on, Feb 8th, 2013

by: WOPRAI

Jay Sole Maintained (ANF) at Hold with Increased Target to $51 on, Feb 8th, 2013

by: WOPRAI

Tom Roderick Maintained (SNCR) at Strong Buy with Increased Target to $324 on, Feb 8th, 2013

by: WOPRAI

Keith Bachman Maintained (TDC) at Hold with Decreased Target to $70 on, Feb 8th, 2013

by: WOPRAI

Andrew Spinola Initiated (ZBRA) at Hold on, Feb 8th, 2013

by: WOPRAI

Brennan Hawken Maintained (STT) at Strong Buy with Increased Target to $62 on, Feb 8th, 2013

by: WOPRAI

Brennan Hawken Maintained (BK) at Hold with Increased Target to $28 on, Feb 8th, 2013

by: WOPRAI

Evan Seigerman Maintained (BIIB) at Buy with Increased Target to $185 on, Feb 8th, 2013

by: WOPRAI

Scott Graham Maintained (THR) at Buy with Decreased Target to $26 on, Feb 8th, 2013

by: WOPRAI

Christopher Horvers Upgraded (AAP) to Buy and Increased Target to $90 on, Feb 8th, 2013

by: WOPRAI

Matthew McClintock Maintained (AAP) at Hold with Increased Target to $75 on, Feb 8th, 2013

by: WOPRAI

Michael Feniger Upgraded (ACM) to Strong Buy and Increased Target to $35 on, Feb 8th, 2013

  • Mon, February 11, 2013

by: WOPRAI

Thomas Diffely Maintained (AMAT) at Strong Buy with Increased Target to $16 on, Feb 11th, 2013

by: WOPRAI

William Katz Maintained (APO) at Strong Buy with Increased Target to $26 on, Feb 11th, 2013

Evan Seigerman Maintained (BIIB) at Buy with Increased Target to $185 on, Feb 8th, 2013

Evan Seigerman of Credit Suisse, Maintained "Biogen Inc." (BIIB) at Buy with Increased Target from $175 to $185 on, Feb 8th, 2013.

Evan has made no other calls on BIIB in the last 4 months.



There are 4 other peers that have a rating on BIIB. Out of the 4 peers that are also analyzing BIIB, 3 agree with Evan's Rating of Hold. Following are those relevant analyst calls for the last 4 months

  • Christopher Raymond of "Piper Sandler" Downgraded from Buy to Hold and Decreased Target to $166 on, Thursday, January 3rd, 2013
  • Jay Olson of "Oppenheimer" Maintained at Hold with Decreased Target to $141 on, Thursday, January 3rd, 2013
  • Sumant Kulkarni of "Canaccord Genuity" Maintained at Hold with Decreased Target to $139 on, Thursday, January 3rd, 2013


This is the rating of the analyst that currently disagrees with Evan

  • Andrew Peters of "Deutsche Bank" Maintained at Strong Buy with Increased Target to $170 on, Wednesday, February 6th, 2013